BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12221641)

  • 1. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
    Barjot C; Hartigan-O'Connor D; Salvatori G; Scott JM; Chamberlain JS
    J Gene Med; 2002; 4(5):480-9. PubMed ID: 12221641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of helper-dependent adenovirus vector relies on helper virus structure and complementing.
    Zhou HS; Zhao T; Rao XM; Beaudet AL
    J Gene Med; 2002; 4(5):498-509. PubMed ID: 12221643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
    Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
    Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a FLP/frt system for generating helper-dependent adenoviral vectors.
    Ng P; Beauchamp C; Evelegh C; Parks R; Graham FL
    Mol Ther; 2001 May; 3(5 Pt 1):809-15. PubMed ID: 11356086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
    Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
    J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors.
    Sargent KL; Ng P; Evelegh C; Graham FL; Parks RJ
    Gene Ther; 2004 Mar; 11(6):504-11. PubMed ID: 14999222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication and packaging of helper-dependent adenoviral vectors.
    Sato M; Suzuki S; Kubo S; Mitani K
    Gene Ther; 2002 Apr; 9(7):472-6. PubMed ID: 11938462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination.
    Umaña P; Gerdes CA; Stone D; Davis JR; Ward D; Castro MG; Lowenstein PR
    Nat Biotechnol; 2001 Jun; 19(6):582-5. PubMed ID: 11385466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress toward gene therapy of Duchenne muscular dystrophy.
    Hartigan-O'Connor D; Chamberlain JS
    Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
    Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA
    Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
    Parks R; Evelegh C; Graham F
    Gene Ther; 1999 Sep; 6(9):1565-73. PubMed ID: 10490766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
    Van Linthout S; Lusky M; Collen D; De Geest B
    Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
    Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
    J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential amplification of adenovirus vectors by flanking the packaging signal with attB/attP-PhiC31 sequences: implications for helper-dependent adenovirus production.
    Alba R; Hearing P; Bosch A; Chillon M
    Virology; 2007 Oct; 367(1):51-8. PubMed ID: 17560622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient in vitro and in vivo excision of floxed sequences with a high-capacity adenoviral vector expressing Cre recombinase.
    Badorf M; Edenhofer F; Dries V; Kochanek S; Schiedner G
    Genesis; 2002 Jul; 33(3):119-24. PubMed ID: 12124944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes.
    Zaupa C; Revol-Guyot V; Epstein AL
    Hum Gene Ther; 2003 Jul; 14(11):1049-63. PubMed ID: 12885345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.
    Fisher KJ; Choi H; Burda J; Chen SJ; Wilson JM
    Virology; 1996 Mar; 217(1):11-22. PubMed ID: 8599194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of viral vectors using recombinase-mediated cassette exchange.
    Nakano M; Odaka K; Takahashi Y; Ishimura M; Saito I; Kanegae Y
    Nucleic Acids Res; 2005 May; 33(8):e76. PubMed ID: 15879348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy.
    Amalfitano A; Chamberlain JS
    Gene Ther; 1997 Mar; 4(3):258-63. PubMed ID: 9135740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations.
    Alemany R; Dai Y; Lou YC; Sethi E; Prokopenko E; Josephs SF; Zhang WW
    J Virol Methods; 1997 Nov; 68(2):147-59. PubMed ID: 9389404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.